Reuters logo
BRIEF-Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
November 15, 2017 / 12:00 AM / 10 days ago

BRIEF-Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma

Nov 14 (Reuters) - Astrazeneca Plc

* Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma

* Astrazeneca - FDA approval based on phase III programme showing up to 51 pct reduction in asthma exacerbations & 75 pct reduction in daily oral steroid use‍​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below